Skip to content

US · NMRA · BIOTECHNOLOGY

Neumora Therapeutics, Inc. Common Stock (NMRA) intrinsic value and stock valuation

$0.33as of 2026-11-21 · Mkt cap 298.31M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Neumora Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values NMRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NMRA’s statements →

Neumora Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 neumoratx.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-236.93M
20202025
Free cash flow
-$-206.44M
20202025
Total equity
$103.9M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-241.16M-$-263.46M-$-188.19M-$-135.87M-$-237.32M
Net income-$-236.93M-$-243.79M-$-235.93M-$-130.9M-$-237.31M
EPSd-$-1.45M-$-1.53M-$-1.49M-$-861.47K-$-1.56M
Operating cash flow-$-206.44M-$-182.94M-$-163.28M-$-114.9M-$-75.42M
Capital expenditure$0.00$0.00-$-120K-$-510K-$-820K
Free cash flow-$-206.44M-$-182.94M-$-163.4M-$-115.41M-$-76.24M
Total assets$191.1M$317M$496.2M$426.2M$429.3M
Total debt$480K$1.85M$5.23M$8.44M$2.05M
Net debt-$-182.05M-$-140.29M-$-368.81M-$-232.5M-$-407.19M
Total equity$103.9M$287.1M$469.1M-$-446.85M-$-325.22M
Cash and short-term investments$182.5M$307.6M$454M$371.9M$409.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$5M$0.00$670K$0.00$0.00
Gross profit-$-5M$0.00-$-670K$0.00$0.00
Research and development expenses$176.1M$200.9M$142.7M$104.8M$212.8M
Selling, general and administrative expenses$60.1M$62.5M$44.8M$31.1M$24.6M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$236.2M$263.5M$187.5M$135.9M$237.3M
Cost and expenses$241.2M$263.5M$188.2M$135.9M$237.3M
Interest income$8.34M$19.9M$16.6M$4.56M$0.00
Interest expense$3.22M$0.00$0.00$0.00$0.00
Depreciation and amortization$210K$630K$670K$590K$540K
Ebitda-$-233.37M-$-242.98M-$-234.99M-$-130.31M-$-236.77M
Operating income-$-241.16M-$-263.46M-$-188.19M-$-135.87M-$-237.32M
Total other income/expenses, net$4.36M$19.9M-$-47.46M$4.97M$10K
Income before tax-$-236.8M-$-243.61M-$-235.66M-$-130.9M-$-237.31M
Income tax expense$130K$180K$270K$0.00$0.00
Net income-$-236.93M-$-243.79M-$-235.93M-$-130.9M-$-237.31M
Weighted average shares outstanding$163.4M$159.4M$158.8M$152M$152M
Weighted average diluted shares outstanding$163.4M$159.4M$158.8M$152M$152M
Balance sheet
20252024202320222021
Cash and short-term investments$182.5M$307.6M$454M$371.9M$409.3M
Net receivables$0.00$0.00$940K$920K$200K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$190.5M$314.1M$478.3M$388M$415.6M
Property, plant and equipment, net$460K$2.92M$6.86M$10.6M$4.04M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$9.85M$23.5M$0.00
Total non-current assets$510K$2.92M$17.9M$38.3M$13.7M
Total assets$191.1M$317M$496.2M$426.2M$429.3M
Accounts payable$3.38M$3.31M$340K$7.15M$1.64M
Short-term debt$280K$1.85M$3.38M$3.37M$1.06M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$32.5M$29.9M$25.1M$23.7M$23.3M
Long-term debt$190K$0.00$1.85M$5.07M$1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$54.7M$20K$2.01M$849.4M$731.2M
Capital lease obligations$0.00$1.85M$5.23M$8.44M$2.05M
Total liabilities$87.2M$29.9M$27.1M$873.1M$754.5M
Common stock$20K$20K$20K$0.00$0.00
Retained earnings-$-1.18B-$-947.22M-$-703.43M-$-467.51M-$-336.61M
Accumulated other comprehensive income (loss)$0.00$60K-$-80K-$-770K$0.00
Total equity$103.9M$287.1M$469.1M-$-446.85M-$-325.22M
Total investments$0.00$165.4M$89.8M$154.5M$0.00
Total debt$480K$1.85M$5.23M$8.44M$2.05M
Net debt-$-182.05M-$-140.29M-$-368.81M-$-232.5M-$-407.19M
Cash flow statement
20252024202320222021
Net income-$-236.93M-$-243.79M-$-235.93M-$-130.9M-$-237.31M
Depreciation and amortization$210K$630K$670K$590K$540K
Stock-based compensation$29.9M$40M$17.2M$8.3M$4.27M
Change in working capital-$-440K$22.6M-$-8.9M-$-6.95M-$-960K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$70K$2.87M-$-580K-$-1.25M-$-760K
Net cash provided by operating activities-$-206.44M-$-182.94M-$-163.28M-$-114.9M-$-75.42M
Investments in property, plant and equipment$0.00$0.00-$-120K-$-510K-$-820K
Acquisitions, net$0.00-$-780K$0.00$0.00$0.00
Net cash used for investing activities$168.5M-$-70.56M$64.4M-$-168.01M-$-820K
Common stock issued$19.9M$13.7M$233.4M$0.00$960K
Common stock repurchased$0.00$0.00-$-490K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$77.1M$21.6M$231.9M$115.7M$293.5M
Net change in cash$39.2M-$-231.89M$133M-$-167.17M$217.3M
Cash at end of period$182.5M$143.4M$375.3M$242.2M$409.4M
Operating cash flow-$-206.44M-$-182.94M-$-163.28M-$-114.9M-$-75.42M
Capital expenditure$0.00$0.00-$-120K-$-510K-$-820K
Free cash flow-$-206.44M-$-182.94M-$-163.4M-$-115.41M-$-76.24M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Neumora Therapeutics, Inc. Common Stock

        Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

        CEO
        Paul L. Berns
        Employees
        96
        Beta
        2.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Neumora Therapeutics, Inc. Common Stock (NMRA)?

        InvestorsCraft does not currently publish an intrinsic value for NMRA. How the IC value is calculated.

        Is NMRA undervalued?

        InvestorsCraft does not publish an undervaluation signal for NMRA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.